Metabolic Not FDA-approved · investigational

Survodutide

BI 456906

Evidence: Studied in humans. Example dose: finalize with a provider. Not a fact-check stamp.

0.3mg (escalating) – 0.6 mg SubQ weekly

Survodutide (BI 456906) is an investigational dual agonist peptide targeting both the glucagon-like peptide-1 (GLP-1) and glucagon receptors, developed by Boehringer Ingelheim and Zealand Pharma. Unlike pure GLP-1 receptor agonists (such as semaglutide), survodutide's dual mechanism is designed to produce weight loss through both appetite suppression (GLP-1 component) and increased energy expenditure and hepatic fat oxidation (glucagon component).

Quick Start

Route

Subcutaneous (SubQ)

Start low

0.3mg SubQ

Frequency

weekly

Timing

No specific requirement

Starting dose. 0.3mg — Escalating

❋

Start here. Every protocol below is ordered lowest-first. Begin at the smallest effective dose, hold about a week to assess tolerance, and step up only if needed.

Tiered Protocols · lowest first

Conservative start

0.3mg (escalating) · Subcutaneous (SubQ) · weekly

conservative starter

0.3mg (escalating)

weekly

Expert

Dual Glucagon/GLP-1 Titration

0.6 mg · SubQ · Weekly

human clinical trial · le Roux et al. 2024 (Lancet Diabetes Endocrinol)

Escalate strictly every 4 weeks: 0.6 mg -> 1.2 mg -> 2.4 mg -> 3.6 mg -> 4.8 mg to mitigate severe nausea.

0.6 mg

Weekly

Reconstitution CalculatorU-100

Vial strength

BAC water

Vials in this mix

Syringe size

Target dose

050100u

Draw to

— units

◆

I will split this dose across more than one syringe

◆

How it works

Activates GLP-1 receptors in the brain (hypothalamus and brainstem) to reduce appetite, slow gastric emptying, and enhance satiety signaling, producing significant caloric intake reduction.

Activates glucagon receptors in the liver and adipose tissue, promoting hepatic fat oxidation, increasing energy expenditure, and mobilizing lipid stores - effects not achieved by GLP-1 agonism alone.

The dual agonist mechanism produces synergistic weight loss: GLP-1 reduces food intake while glucagon increases energy expenditure, targeting both sides of the energy balance equation.

What to expect

Early

Days 1–7

Weeks 1-4: Reduced appetite and early weight loss during dose titration. GI side effects most common in this phase.

Evidence

HumanPresent

AnimalPresent

In-vitroPresent

Each reference below was re-fetched from its PubMed record, and the quoted sentence was confirmed to appear in that abstract and to support the claim it sits under. Follow any of them to read the source.

The aim of this study was to assess the dose-response effects of the subcutaneous glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide (BI 456906) on HbA1c levels and bodyweight reduction.

The aim of this study was to assess the dose-response effects of the subcutaneous glucagon receptor/glucagon-like peptide-1 receptor dual agonist survodutide (BI 456906) on HbA1c levels and bodyweight reduction.

Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial. Diabetologia · 2024 · PMID 38095657

Evidence scope. Human phase 2 type 2 diabetes dose-response trial; supports route and dual agonism, not the exact 0.3 mg weekly starter.

Claims we could not support

No abstract we checked supports these for this molecule at this route. That is not the same as saying they are false — it marks where the evidence is missing.

Dose/route: 0.3mg (escalating) via Subcutaneous (SubQ), weekly. No checked live PubMed abstract supported this complete molecule/formulation/route/dose/frequency combination.

Primary safety claim: Nausea (most common, especially during dose titration). No checked live abstract directly established this as the primary concern for the card's exact formulation and regimen.

Interactions & stacking

Two different questions: what is documented about running these together, and what is documented about drawing them into the same syringe. A good pharmacological partner can still have to be pinned separately.

Documented together

BPC-157Tissue repair peptide does not interfere with incretin signaling

Testosterone CypionateHormone replacement and GLP-1/glucagon agonist address different metabolic pathways

NAD+Cellular energy support and incretin therapy act through independent mechanisms

Urolithin AMitophagy activator and dual incretin agonist address different aspects of metabolic health

Keep separate

MK-677MK-677 strongly increases appetite and worsens insulin resistance, directly opposing survodutide metabolic benefits

SemaglutideBoth are GLP-1 receptor agonists - overlapping receptor targets increase risk of severe GI side effects without additional benefit

TirzepatideBoth activate GLP-1 receptors - co-administration risks excessive GLP-1 stimulation and severe nausea/vomiting

LiraglutideConcurrent GLP-1 agonism from two agents risks compounded GI adverse effects and hypoglycemia

Check any specific pair in the Stack & Interaction Checker, which answers both questions separately. Absence of a documented conflict is not evidence of safety.

Pharmacokinetics

Illustrative plasma concentration · 16 d

Half-life

~3-4 days

Supports weekly dosing

Peak · Tmax

1-3 days

SubQ

Elimination

~15-20 days

Bioavailability

~65-80%

SubQ (estimated from class)

Duration of action

7 days

Supports weekly dosing; appetite suppression and metabolic effects sustained between doses

Clearance

Enzymatic degradation and renal elimination

Storage. Store refrigerated at 2-8C. Do not freeze. Protect from light.

Regulatory status

Investigational - not yet approved by FDA or any regulatory agency. Phase 3 clinical trials ongoing (SYNCHRONIZE program by Boehringer Ingelheim). Breakthrough Therapy designation for MASH.

Put it to work

Calculate, log & track

Open Survodutide straight into OnePin with your vial and dose pre-filled, then let it handle the syringe math and remind you before the vial runs out.

Open Survodutide in the app →

Go deeper

The guide & community

The complete Survodutide walkthrough, real protocol discussion and coaching live inside the BlessUp community on Skool.

Join the community ↗

Open in app Community